{"id":"NCT01165554","sponsor":"GE Healthcare","briefTitle":"Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels","officialTitle":"A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2010-07-20","resultsPosted":"2013-12-04","lastUpdate":"2013-12-04"},"enrollment":203,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Brain Fibrillarab Levels"],"interventions":[{"type":"DRUG","name":"[18F] Flutemetamol","otherNames":["AH110690"]}],"arms":[{"label":"[18F] Flutemetamol","type":"EXPERIMENTAL"}],"summary":"To determine the level of association between quantitative regional estimates of brain uptake of \\[18F\\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.","primaryOutcome":{"measure":"The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid Î².","timeFrame":"Post flutemetamol administration.","effectByArm":[{"arm":"Sensitivity Percentage of Abnormal Visual Reads","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["38048354","37777806","31727169","30123935","27955679"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":180},"commonTop":[]}}